Medicine and Dentistry
Oncology
96%
Non-Hodgkin Lymphoma
87%
Doxorubicin
62%
CHOP
58%
Disease
51%
Vincristine
49%
Cyclophosphamide
48%
Overall Survival
40%
Prednisone
39%
Neoplasm
37%
Diffuse Large B-Cell Lymphoma
34%
Radiation Therapy
31%
Follicular Lymphoma
29%
Progression Free Survival
27%
Hodgkin's Lymphoma
27%
Rituximab
25%
Large-Cell Lymphoma
25%
B Cell
23%
Phase II Trials
23%
Lymphoma
21%
Prognostic Factor
21%
Combination Chemotherapy
19%
Gene Expression
19%
T Cell
19%
Peripheral T-Cell Lymphoma
18%
Clinical Trial
17%
Group Trial
17%
Breast Cancer
15%
Tositumomab
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Cisplatin
13%
Survival Rate
12%
Nodular Melanoma
11%
Bleomycin
11%
Etoposide
11%
Involved-Field Radiotherapy
11%
Gene Expression Profiling
11%
Arm
10%
Chemotherapy Regimens
10%
Methotrexate
9%
Patient with Non-Hodgkins Lymphoma
8%
Lymphocytic Lymphoma
8%
Histiocytic Lymphoma
8%
Radioimmunotherapy
8%
Malignant Neoplasm
8%
B-Cell Lymphoma
8%
Iodine 131
8%
Major Histocompatibility Complex
8%
Leukemia
7%
Recurrence Free Survival
7%
Large Cell
7%
Morphology
7%
Biopsy
7%
Molecular Profiling
7%
Burkitt's Lymphoma
7%
Myeloma
7%
Nerve Cell Adhesion Molecule
7%
Immune Checkpoint Inhibitor
7%
Vindesine
7%
T Lymphocyte
7%
Prostate Cancer
7%
Skin Defect
7%
Esorubicin
7%
Monoclonal Antibody Ki 67
7%
Adriamycin Bleomycin Vinblastine Dacarbazine
7%
Mitoxantrone
7%
Germinal Center
6%
Androgen Deprivation Therapy
6%
Nuclease
6%
Hazard Ratio
6%
Immunophenotyping
6%
Failure Free Survival
5%
Formaldehyde
5%
Levamisole
5%
Mitomycin
5%
Histocompatibility Antigen
5%
Vinblastine
5%
Mycobacterium Bovis BCG
5%
Folinic Acid
5%
Immunocompetent Cell
5%
Computer Assisted Tomography
5%
Positron Emission Tomography
5%
Follicular Lymphoma International Prognostic Index
5%
International Prognostic Index
5%
Adverse Event
5%
Disease Free Survival
5%
Cell Adhesion Molecule
5%
Keyphrases
Southwest Oncology Group
82%
Group Studies
46%
Prednisone
41%
Diffuse Large B-cell Lymphoma (DLBCL)
39%
Cyclophosphamide
36%
Chemotherapy
33%
Doxorubicin
31%
Overall Survival
26%
Non-Hodgkin Lymphoma
26%
Progression-free Survival
25%
Follicular Lymphoma
22%
Complete Remission
20%
High-grade non-Hodgkin Lymphoma
19%
Lymphoma
19%
Phase II Trial
18%
Outcome-based Contracts
18%
Pricing Method
18%
Median Survival
17%
Phase II Study
16%
Methotrexate
15%
Non-small Cell Lung Cancer (NSCLC)
15%
Combination Chemotherapy
15%
Etoposide
14%
Partial Response
14%
Complete Response
13%
Rituximab
13%
Mitomycin C
13%
United States
12%
Hodgkin Disease
12%
Lymphoma Patients
11%
Confidence Interval
11%
Osimertinib
11%
Malignant Lymphoma
11%
Complete Response Rate
11%
Palestinians
11%
Mitoxantrone
11%
Meta-analysis
11%
Grammatical Complexity
11%
Doxorubicin-cyclophosphamide
10%
Initial Treatment
10%
Cisplatin
10%
Unfavorable Histology
10%
Monoclonal Antibody
10%
Clinical Trials
10%
HLA-DR
9%
Radioimmunotherapy
9%
Prognostic Significance
9%
Bleomycin
9%
5-fluorouracil (5-FU)
9%
Advanced Stage
8%
Prognostic Factors
8%
Bis-pyrene
8%
Acquisition Cost
8%
Objective Response
8%
Aggressive non-Hodgkin Lymphoma
8%
Outcome Prediction
8%
Positioning Analysis
8%
Molecular Diagnostics
8%
Monte Carlo Simulation
8%
Mantle Cell Lymphoma
8%
Tositumomab
7%
Intermediate Grade
7%
Survival Prediction
7%
Melanoma
7%
Outcome-based Pricing
7%
Clinical Outcomes
7%
Response Rate
7%
Gene Expression
7%
Queerness
7%
Ki-67
7%
Vindesine
7%
MACOP-B
7%
Bucindolol
7%
Talimogene Laherparepvec (T-VEC)
7%
Limited Disease
7%
Ipilimumab
7%
MLN8237
7%
Combination Therapy
7%
Chemotherapy Failure
7%
Salvage Radiotherapy
7%
Large Cell Undifferentiated Carcinoma
7%
L2 English
7%
Disciplinary Writing
7%
Economic Evaluation
7%
Radiation Therapy
7%
Language Teacher Agency
7%
Iodine-131 (131I)
7%
Second Language Learning
7%
CHOP Chemotherapy
7%
No Significant Difference
7%
Positioning Theory
7%
Chemotherapy Regimen
6%
Complexity Features
6%
Involved Field Radiotherapy
6%
Prospective Cohort Study
6%
Peripheral T-cell Lymphoma
6%
Gameful
6%
Neutropenic
6%
Lymphoma Cells
6%
Gene Expression Profiling
6%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Chemotherapy
87%
Doxorubicin
77%
Vincristine
69%
Cyclophosphamide
67%
Prednisone
51%
Disease
51%
Overall Survival
37%
Progression Free Survival
34%
Rituximab
29%
Clinical Trial
29%
Methotrexate
27%
Remission
25%
Hodgkin Disease
25%
Non Small Cell Lung Cancer
25%
Phase II Trials
24%
Bleomycin
22%
Osimertinib
20%
Follicular Lymphoma
20%
Neoplasm
19%
Tositumomab
19%
Etoposide
19%
Lymphoma
19%
Melanoma
14%
Cisplatin
14%
Mantle Cell Lymphoma
13%
Diffuse Large B Cell Lymphoma
13%
Verapamil
13%
Iodine-131
12%
Breast Cancer
12%
Bisantrene
11%
Small Cell Lung Cancer
11%
Vindesine
11%
Mitoxantrone
11%
Chemotherapy Regimens
11%
Large Cell Lymphoma
11%
Survival Rate
10%
Cytarabine
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Ipilimumab
9%
Malignant Neoplasm
8%
Epidermal Growth Factor Receptor
8%
Mitomycin
8%
Adenocarcinoma
8%
Group Trial
7%
Adverse Event
7%
Recurrence Free Survival
7%
Docetaxel
7%
Lymphocytic Lymphoma
7%
Combination Therapy
7%
Bucindolol
7%
Talimogene Laherparepvec
7%
Galiximab
7%
Esorubicin
7%
Alisertib
7%
Dexamethasone
7%
Monoclonal Antibody Ki 67
6%
Monoclonal Antibody
5%
Folinic Acid
5%
Epileptic Absence
5%
Vinblastine
5%
Levamisole
5%
Randomized Controlled Trial
5%
Mycobacterium Bovis BCG
5%
Failure Free Survival
5%
Paclitaxel
5%